Amprion, Modality.AI Break New Ground in Multimodal Assessment for Neurodegenerative Disease

Amprion and Modality.AI are teaming up to explore the ways in which molecular biomarkers and objective digital assessments can be combined to improve the characterization of central nervous system (CNS) disorders.

The collaboration brings together Amprion’s expertise in detecting disease-specific misfolded proteins with Modality.AI’s browser-based Tina platform, which uses structured audiovisual conversations to generate objective measures of speech, language, facial expression, cognition, and behavior to track disease progression. Together, the companies aim to better characterize and monitor patients, support clinical research, and generate richer datasets for neurodegenerative disease studies.

“Neurodegenerative diseases aren’t defined by a single signal, and they shouldn’t be assessed that way,” Amprion Co-Founder/CEO Russ Lebovitz, M.D., Ph.D., stated. “At Amprion, our work has always been rooted in revealing the underlying biology of disease. By bringing together molecular biomarkers and scalable digital assessments, we have an opportunity to connect what’s happening biologically with how disease presents and progresses in patients. That more complete picture can support better research, more informed clinical decision-making, and ultimately better patient outcomes.”

Initially, the collaboration will explore applications across clinical research, observational cohorts, and biopharma-sponsored studies where paired molecular and digital assessments may improve patient stratification, reduce biological heterogeneity, monitor disease progression, and generate evidence to support future therapeutic development.

Early areas of focus are expected to include Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy (MSA), ALS, and related neurodegenerative disorders.

The collaboration reflects a broader movement toward multimodal approaches in neuroscience research. As biomarker science and digital health technologies continue to evolve, integrating biological and functional data may provide a more complete understanding of disease progression while supporting the development of precision medicine approaches for neurodegenerative disorders.

“CNS disorders are complex, heterogeneous diseases that cannot be fully understood through any single measurement,” Modality.AI Founder/CEO David Suendermann-Oeft, Ph.D., stated. “Combining biological insight with objective digital measures has the potential to provide a more complete understanding of how these diseases develop and progress.”

Amprion’s SAAmplify-ɑSYN test is a first-in-class qualitative Laboratory Developed Test and the only seed amplification assay available to aid the diagnosis of synucleinopathies such as Parkinson’s disease, Lewy body dementia, and Alzheimer’s disease with Lewy body co-pathology. The U.S. Food and Drug Administration granted Amprion a Breakthrough Device Designation in 2019 for use of the test as an aid in Parkinson’s disease diagnosis. The test became commercially available in the United States in 2021.

Amprion advances the diagnosis of neurodegenerative disorders through seed amplification testing. SAAmplify-ɑSYN is the only seed amplification assay available to aid the diagnosis of synucleinopathies such as Parkinson’s disease, Lewy body dementia, and Alzheimer’s disease with Lewy body co-pathology.

Modality.AI provides technology for the objective assessment of central nervous system conditions through automated speech, language, facial, cognitive, and behavioral analytics elicited by Tina, a virtual clinical guide. Modality’s browser-based platform is designed for use in decentralized and site-based clinical studies, enabling standardized, scalable, and patient-centered assessments across neurological and psychiatric conditions.